✦ LIBER ✦

Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects

✍ Scribed by Allavena, C.; Dailly, E.; Reliquet, V.; Bonnet, B.; Pineau, S.; Andre-Garnier, E.; Boutoille, D.; Bouquie, R.; Raveleau, A.; Bouchez, S.; Billaud, E.; Raffi, F.

Book ID: 126477265
Publisher: Oxford University Press
Year: 2014
Tongue: English
Weight: 179 KB
Volume: 69
Category: Article
ISSN: 0305-7453
DOI: 10.1093/jac/dku187

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Switching to emtricitabine, tenofovir an

Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study

✍ Gantner, P; Reinhart, S; Partisani, M; Baldeyrou, M; Batard, M-L; Bernard-Henry, 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Emtricitabine/Rilpivirine/Tenofovir Diso

Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Guide to Its Use in HIV-1 Infection

✍ Katherine A. Lyseng-Williamson, Lesley J. Scott 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 169 KB

Effectiveness and safety of simplificati

Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada®) in virologically suppressed HIV-infected patients on HAART

✍ R. Palacios; C. Hidalgo; M. J. Ríos; A. Rivero; L. Muñoz; F. Lozano; V. Gutiérre 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 101 KB

Elvitegravir/Cobicistat/Emtricitabine/Te

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Stribild®): A Review of Its Use in the Management of HIV-1 Infection in Adults

✍ Perry, Caroline M. 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 574 KB

Switching to coformulated elvitegravir,

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

✍ Pozniak, Anton; Markowitz, Martin; Mills, Anthony; Stellbrink, Hans-Juergen; Ant 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 274 KB

Budget Impact of the Introduction of Elv

Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for HIV Treatment, to Third Party Payers in the United States

✍ Brogan, A.; Talbird, S.E.; Thompson, J.R.; Kim, Y.A.; Olson, J.; Peterson, J.; P 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB